Albert Einstein College Of Medicine

Albert Einstein College of Medicine, a private tax-exempt educational institution and child entity within the Montefiore Medical Center corporate structure headquartered in the Bronx, New York, operates as a prime recipient on federal grants and contracts spanning biomedical research, epidemiological studies, and clinical training programs. The institution does not hold federal contract vehicles; instead, it receives task orders and grants from the Department of Health and Human Services National Institutes of Health and other federal agencies funding hypothesis-driven research across cancer biology, cardiovascular health, infectious diseases, aging, immunology, and neuroscience.

Einstein's federal footprint is heavily concentrated in NIH research grants. The National Heart, Lung, and Blood Institute leads customer concentration by both award count and dollar magnitude—170 awards carrying $89.8 million in combined potential value—followed by the National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institute on Aging. The five leading institutes account for 54% of recent awards. Einstein also holds a $25 million single-award Indefinite Delivery Contract with the National Heart, Lung, and Blood Institute for the Hispanic Community Health Study—Study of Latinos (HCHS-SOL) Bronx Field Center, with the first task order executed November 30, 2024, carrying a $16.69 million ceiling for cost-reimbursement delivery running through November 29, 2032. This IDC anchors long-term epidemiological work in a diverse Hispanic/Latino cohort, with Einstein responsible for participant enrollment, health assessments, data collection and management, specimen collection, and analysis of cardiovascular and metabolic health outcomes.

Einstein's recent award activity shows strong engagement across the NIH ecosystem. In 2024, the institution received 225 awards; activity declined to 140 in 2025 and 132 in 2026, with only three awards recorded for early 2027. The recompete exposure within the next twenty-four months spans 213 awards carrying $175 thousand in combined potential value—modest in dollar magnitude but operationally significant given the volume of grants reaching completion or renewal. Representative prime work illustrates Einstein's research scope. The National Cancer Institute awarded $2.038 million on August 26, 2026, for a Project Grant (P01CA295557) investigating mechanisms of early breast cancer local and distant relapse through disseminated tumor cell dormancy, cyst formation, and tissue microenvironment interactions. The National Institute of Allergy and Infectious Diseases awarded $3.204 million on June 18, 2026, to study TAR RNA binding to INI1/SMARCB1 and its role in HIV-1 transcriptional regulation and latency reactivation. The National Heart, Lung, and Blood Institute awarded $1.6 million on August 15, 2026, to investigate Wnt/beta-catenin signaling in vascular remodeling relevant to atherosclerosis and restenosis. The National Institute on Aging awarded $1.89 million on July 1, 2026, for research on chaperone-mediated autophagy in aging-associated cardiovascular fibrosis. These awards exemplify Einstein's positioning as a leading recipient of NIH investigator-initiated research funding in basic and translational life sciences.

Einstein operates predominantly as a prime on its federal award portfolio—72% of 1,398 total awards (prime and sub combined across all federal sources) carry prime status; 28% are subcontractor positions. On service contracts captured in the Service Contract Inventory database, SCI-reportable invoicing totaled $3.8 million across FY2022–FY2025, with FY2022 showing $2.1 million across 14.2 FTEs and FY2023 showing $1.7 million across 8.9 FTEs; subsequent years carried zero or minimal SCI reportage, indicating that Einstein's federal revenue stream is dominated by research grants and delivery orders on IDCs rather than by service contracts above the $150,000 SCI threshold. Across SCI-reportable prime contracts, government-paid hourly rates ranged from $69.40/hr (10th percentile) to $187.34/hr (90th percentile), with a median of $90.19/hr. The vendor engaged no subcontractors on average across its SCI-reportable prime contracts (0% sub-hours share).

When Einstein operates as a subcontractor, it typically partners with large research universities and medical institutions on grant subawards. Recent sub-recipient positions include work under the University of Texas Health Science Center at Houston on blood proteomic signatures of diabetes and gut dysbiosis in Hispanic/Latino populations, under Duke University on HIV and lupus research, under Columbia University on tuberculosis drug-resistance detection, and under Cornell and Pennsylvania universities on neuroscience and immunology projects. These subawards position Einstein as a specialized research site or analytical unit within multi-institutional consortia, particularly leveraging its HCHS-SOL field center infrastructure and its epidemiological expertise in diverse urban populations.

Einstein's customer agency concentration underscores its NIH-centric mission. Approximately 99% of combined potential value flows from HHS-NIH institutes and the National Heart, Lung, and Blood Institute alone accounts for $89.8 million (92% of the reportable total). The Department of the Navy places smaller awards (16 awards, $757 thousand) for tuition, fees, and research services. The Defense Health Agency has funded anaplastic thyroid cancer research and surgical stress-resilience studies at modest scale. The absence of Department of Defense contract IDVs, GWAC seats, or other commercial acquisition vehicles reflects Einstein's exclusive positioning within the federal research and training grants ecosystem rather than the federal services contracting market.

The institutional structure reflects Einstein's role as a child entity within Montefiore Medical Center, a major teaching hospital and health system. This corporate relationship facilitates clinical research networks, patient recruitment cohorts (particularly the HCHS-SOL), and integrated care delivery platforms for translational research. Combined obligated dollars across all Einstein awards exceed $3.68 billion—substantially higher than the $97.9 million combined potential value reported in the source, a pattern indicating that many awards have been funded across multiple fiscal years and renewal cycles, with obligated amounts reflecting historical accumulation rather than new contract ceilings.